Daclahep (Daclatasvir Dihydrochloride 60mg )
- BrandDaclahep 60mg Daclatasvir
- Country of manufactureIndia
- Dosage formPills
- DaclahepDaclahep 60mg Daclatasvir
- Hepatitis C28
- Strength60 mg
Prescribing Information: Daclatasvir (DACLAHEP) Full Prescribing Information.Summary: Daclatasvir plus sofosbuvir is an all-oral, with or without ribavirin is an option for the treatment of genotype 1 or 3 chronic HCV across a variety of patient populations. Based on the results of the phase 3 ALLY trials, daclatasvir and sofosbuvir is an effective, albeit very expensive option for patients with genotype 1 or 3 HCV, including those with cirrhosis, HIV coinfection, or post-liver transplantation. The use of daclatasvir with sofosbuvir has provided an important ribavirin-free oral option for genotype 3 patients, but the 12 week dual therapy has limited efficacy in cirrhotic genotype 3 patients. Cost, lack of coformulation, and the recommendation of baseline NS5A testing in genotype 1a cirrhotic patients make daclatasvir plus sofosbuvir a less compelling option in this subset of patients.